

## Press Release

---

# Nicox: Half-year liquidity contract statement with Kepler Cheuvreux

---

July 6, 2021 – release at 7:30 am CET  
Sophia Antipolis, France

Under the liquidity contract entered into between NICOX and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th 2021:

- 218,919 shares
- € 128,032.29
  
- Number of executions on buy side on semester: 1,594
- Number of executions on sell side on semester: 1,298
- Traded volume on buy side on semester: 978,682 shares for € 4,245,529.01
- Traded volume on sell side on semester: 906,908 shares for € 3,977,929.37

As a reminder :

• the following resources appeared on the last half year statement on 31 December 2020 on the liquidity account:

- 147,145 shares
- € 395,631.93
  
- Number of executions on buy side on semester: 829
- Number of executions on sell side on semester: 609
- Traded volume on buy side on semester: 457,955 shares for € 1,916,480.01
- Traded volume on sell side on semester: 310,810 shares for € 1,312,111.94

• the following resources appeared on the liquidity account when the activity started:

- 0 shares
- € 500,000.00

The liquidity agreement complies with AMF Decision n° 2018-01 dated 2nd July 2018, introducing liquidity agreements on equity securities as permitted market practice.

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
<b>Total</b>	<b>1,594</b>	<b>978,682</b>	<b>4,245,529.01</b>	<b>1,298</b>	<b>906,908</b>	<b>3,977,929.37</b>
04/01/2021	20	15,629	67,673.57	7	3,400	15,028.00
05/01/2021	25	8,621	37,156.51	16	11,200	48,944.00
06/01/2021	1	2,000	8,720.00	21	12,400	54,808.00
07/01/2021	14	9,750	42,217.50	9	7,800	34,164.00
08/01/2021	4	3,000	13,200.00	9	9,705	42,993.15
11/01/2021	13	9,401	41,834.45	23	16,295	73,001.60
12/01/2021	3	1,999	8,915.54	24	16,064	72,609.28
13/01/2021	-	-	-	39	16,200	75,008.00
14/01/2021	20	16,270	75,818.20	2	545	2,594.20
15/01/2021	8	6,716	31,027.92	12	11,455	54,182.15
18/01/2021	5	5,120	23,910.40	33	28,000	134,680.00
19/01/2021	30	18,000	89,280.00	3	5,400	27,432.00
20/01/2021	10	6,301	31,252.96	7	5,000	25,400.00
21/01/2021	38	25,000	122,250.00	3	2,000	10,160.00
22/01/2021	35	20,000	94,000.00	8	6,000	28,500.00
25/01/2021	23	12,341	56,398.37	-	-	-
26/01/2021	6	3,059	13,765.50	6	9,464	43,439.76
27/01/2021	28	14,130	63,443.70	6	5,400	24,948.00
28/01/2021	27	15,520	68,443.20	16	15,000	67,200.00
29/01/2021	24	10,000	43,800.00	-	-	-
01/02/2021	-	-	-	31	30,000	133,800.00
02/02/2021	10	7,000	31,500.00	19	10,000	45,800.00
03/02/2021	-	-	-	35	22,000	100,980.00
04/02/2021	17	8,773	40,092.61	8	9,900	45,936.00
05/02/2021	19	16,227	73,995.12	16	12,000	55,320.00
08/02/2021	23	22,000	99,220.00	4	2,000	9,240.00
09/02/2021	22	12,000	54,000.00	4	2,000	9,160.00
10/02/2021	2	799	3,595.50	8	4,001	18,164.54
11/02/2021	12	12,000	54,120.00	7	4,777	21,687.58
12/02/2021	33	13,500	60,345.00	-	-	-
15/02/2021	4	4,000	18,240.00	47	23,322	107,047.98
16/02/2021	8	6,000	27,420.00	8	8,000	37,040.00
17/02/2021	11	12,000	54,840.00	-	-	-
18/02/2021	15	6,000	27,180.00	-	-	-
19/02/2021	7	3,500	15,680.00	4	4,000	18,200.00
22/02/2021	13	11,000	49,940.00	10	6,328	28,918.96
23/02/2021	32	23,172	104,274.00	24	19,672	90,884.64
24/02/2021	2	2,001	8,984.49	8	4,980	22,659.00
25/02/2021	10	7,018	31,721.36	2	3,020	13,801.40
26/02/2021	32	14,881	66,071.64	-	-	-
01/03/2021	5	4,001	17,884.47	16	15,000	68,250.00
02/03/2021	17	9,999	44,495.55	-	-	-
03/03/2021	23	13,400	58,692.00	11	6,075	27,033.75
04/03/2021	26	16,400	70,848.00	30	15,830	69,335.40
05/03/2021	16	12,799	54,011.78	-	-	-
08/03/2021	9	7,000	29,750.00	20	16,000	68,480.00
09/03/2021	8	2,127	9,082.29	7	10,000	43,300.00
10/03/2021	5	3,473	14,899.17	13	16,000	69,440.00
11/03/2021	-	-	-	16	12,000	52,560.00
12/03/2021	-	-	-	34	22,095	98,101.80
15/03/2021	-	-	-	32	22,000	99,440.00

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
<b>Total</b>	<b>1,594</b>	<b>978,682</b>	<b>4,245,529.01</b>	<b>1,298</b>	<b>906,908</b>	<b>3,977,929.37</b>
16/03/2021	-	-	-	18	13,395	81,081.20
17/03/2021	15	10,001	45,004.50	7	2,605	11,878.80
18/03/2021	18	10,047	44,910.09	8	8,000	38,240.00
19/03/2021	30	20,000	88,800.00	-	-	-
22/03/2021	14	10,000	43,800.00	-	-	-
23/03/2021	22	14,831	64,366.54	1	1	4.42
24/03/2021	16	13,570	57,672.50	-	-	-
25/03/2021	16	10,537	44,466.14	-	-	-
26/03/2021	-	-	-	1	2,000	8,520.00
29/03/2021	7	1,409	5,988.25	14	8,000	34,160.00
30/03/2021	18	6,001	25,264.21	-	-	-
31/03/2021	-	-	-	9	6,374	27,089.50
01/04/2021	-	-	-	41	27,625	119,892.50
06/04/2021	13	11,000	47,960.00	11	4,000	17,920.00
07/04/2021	4	3,000	13,140.00	2	51	225.42
08/04/2021	8	7,019	30,673.03	4	2,401	10,588.41
09/04/2021	2	1,981	8,676.78	25	13,878	61,340.76
12/04/2021	16	16,000	69,600.00	-	-	-
13/04/2021	16	11,001	47,084.28	1	252	1,083.60
14/04/2021	3	1,129	4,809.54	17	6,009	25,838.70
15/04/2021	21	10,000	42,600.00	-	-	-
16/04/2021	15	6,001	25,684.28	11	10,360	44,858.80
19/04/2021	11	9,927	41,891.94	1	257	1,094.82
20/04/2021	12	4,000	16,640.00	-	-	-
21/04/2021	8	4,200	17,304.00	-	-	-
22/04/2021	4	2,800	11,452.00	6	4,000	16,600.00
23/04/2021	2	2,000	8,200.00	7	4,800	19,968.00
26/04/2021	21	10,322	41,804.10	3	5,100	20,910.00
27/04/2021	-	-	-	29	22,843	96,169.03
28/04/2021	4	4,000	16,640.00	9	6,074	25,571.54
29/04/2021	17	14,656	61,262.08	17	7,927	33,610.48
30/04/2021	22	12,071	49,973.94	-	-	-
03/05/2021	9	5,322	21,979.86	6	3,405	14,130.75
04/05/2021	12	7,053	29,128.89	12	8,595	35,927.10
05/05/2021	5	3,899	16,063.88	50	32,657	137,159.40
06/05/2021	24	20,000	83,600.00	1	2,000	8,520.00
07/05/2021	-	-	-	11	6,000	25,440.00
10/05/2021	10	8,275	34,920.50	12	10,000	42,600.00
11/05/2021	25	16,205	66,926.65	-	-	-
12/05/2021	12	6,277	26,049.55	-	-	-
13/05/2021	15	8,208	33,652.80	35	26,000	108,940.00
14/05/2021	23	20,985	86,877.90	4	2,000	8,440.00
17/05/2021	11	8,564	35,369.32	5	4,000	16,640.00
18/05/2021	1	1	4.18	12	8,000	33,440.00
19/05/2021	21	9,999	41,595.84	16	10,000	42,100.00
20/05/2021	5	3,138	13,148.22	10	8,000	33,840.00
21/05/2021	19	12,138	50,858.22	24	16,000	68,640.00
24/05/2021	12	8,724	36,204.60	-	-	-
25/05/2021	15	6,457	26,602.84	14	8,115	33,596.10
26/05/2021	10	4,980	20,467.80	1	1	4.14
27/05/2021	9	6,000	24,660.00	17	5,736	23,689.68

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
<b>Total</b>	<b>1,594</b>	<b>978,682</b>	<b>4,245,529.01</b>	<b>1,298</b>	<b>906,908</b>	<b>3,977,929.37</b>
28/05/2021	9	4,530	18,527.70	28	26,649	110,593.35
31/05/2021	15	6,346	26,272.44	9	4,051	16,973.69
01/06/2021	2	1,443	5,974.02	27	16,218	68,277.78
02/06/2021	3	6,000	25,140.00	9	4,095	17,280.90
03/06/2021	23	8,411	35,073.87	2	2,000	8,380.00
04/06/2021	28	13,800	57,132.00	-	-	-
07/06/2021	5	4,683	19,340.79	6	2,050	8,487.00
08/06/2021	10	4,103	17,068.48	12	9,950	41,591.00
09/06/2021	21	13,214	54,441.68	-	-	-
10/06/2021	11	6,001	24,544.09	2	696	2,874.48
11/06/2021	6	4,238	17,248.66	13	4,347	17,822.70
14/06/2021	2	31	127.10	25	12,390	51,170.70
15/06/2021	4	2,292	9,443.04	2	975	4,046.25
16/06/2021	20	7,989	32,675.01	-	-	-
17/06/2021	13	5,138	20,808.90	-	-	-
18/06/2021	17	5,443	21,826.43	-	-	-
21/06/2021	38	18,450	72,139.50	-	-	-
23/06/2021	10	7,400	28,194.00	3	2,260	8,723.60
24/06/2021	-	-	-	22	26,740	102,414.20
25/06/2021	13	8,000	30,720.00	5	2,000	7,780.00
28/06/2021	11	6,000	22,860.00	-	-	-
29/06/2021	2	1,000	3,770.00	3	3,698	14,089.38
30/06/2021	25	6,515	24,431.25	-	-	-

## About Nicox

Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIAE® in allergic conjunctivitis, licensed in multiple geographies, including to EyeVance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets.

Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: [www.nicox.com](http://www.nicox.com).

## Analyst coverage

Bryan, Garnier & Co	Victor Floc'h	Paris, France
Cantor Fitzgerald	Louise Chen	New York, U.S.
Edison Investment Research	Pooya Hemami	London, UK
H.C. Wainwright & Co	Yi Chen	New York, U.S.
Kepler Cheuvreux	Damien Choplain	Paris, France



*The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.*

## Contacts

### Nicox

Gavin Spencer  
Executive Vice President, Chief Business Officer  
& Head of Corporate Development  
T +33 (0)4 97 24 53 00  
[communications@nicox.com](mailto:communications@nicox.com)

Investors & Media  
United States & Europe  
LifeSci Advisors, LLC  
Mary-Ann Chang  
T +44 7483 284 853  
[mchang@lifesciadvisors.com](mailto:mchang@lifesciadvisors.com)

Media  
France  
LifeSci Advisors, LLC  
Sophie Baumont  
M +33 (0)6 27 74 74 49  
[sophie@lifesciadvisors.com](mailto:sophie@lifesciadvisors.com)

---

### Forward-Looking Statements

---

The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in the 3<sup>rd</sup> chapter of the '*Document d'enregistrement universel, rapport financier annuel et rapport de gestion 2020*' filed with the French *Autorité des Marchés Financiers* (AMF) on March 1, 2021 which are available on Nicox's website ([www.nicox.com](http://www.nicox.com)).

**Nicox S.A.**  
Drakkar 2  
Bât D, 2405 route des Dolines  
CS 10313, Sophia Antipolis  
06560 Valbonne, France  
T +33 (0)4 97 24 53 00  
F +33 (0)4 97 24 53 99